The
global Fluorescent
In Situ Hybridization (Fish) Probe Market size is expected to reach USD 1.04 billion by 2026, according to
a new report by Grand View Research, Inc. It is projected to register a CAGR of 6.8% during the forecast
period. Increasing global population prone to target diseases and demand for
accurate and effective diagnostics of these diseases are the factors attributed
to the growth. Increasing use of FISH probes in vitro diagnosis of various
infectious diseases is expected to create growth opportunities in near future.
In
addition, supportive government initiatives, rising healthcare expenditure and
awareness pertaining to the benefits associated with FISH probe technique are
expected to drive the market growth during forecast period. Furthermore,
technological advancement in Chromogenic In Situ Hybridization (CISH) such as
higher storage time for analyzed samples for long duration studies is expected
to fuel the demand.
FISH
is most commonly used for the detection of genetic diseases such as Angelman
syndrome, Prader-Willi syndrome, chronic myelogenous leukemia, Down’s syndrome,
Velocardiofacial syndrome, 22q13 deletion syndrome, acute lymphoblastic
leukemia, and cri-du-chat. The genetic disease segment led the overall market
in 2018. The probe does not require live cells and can quantify automatically
as compared to the conventional cytogenetics, and is more convenient and
effective. This factor is anticipated to propel the segment growth. According
to a publication from the Centers for Disease Control and Prevention (CDC) in
2018, Down’s syndrome was the most common genetic disorders with almost one in
every 700 new newborns affected by the disorder.
Related Press Release@ FISH Probe Market
FISH Probe Market Report Highlights
- Companion
diagnostics is expected to command the largest market share of end use
segment. Used in personalized medicine, it includes medical decision,
products, and practices based on patient’s genetic, clinical, and genomic
information
- In oncology,
major companion diagnostics are based on the FISH owing to higher
reliability, sensitivity, accuracy, and procedure reproducibility, which
are less affected by analytical variables and tissue fixation as compared
to immunohistochemistry
- miRNA is
expected to be the fastest growing RNA segment, driven by factors such as
increasing R&D and extensive usage in cancer detection
- Asia Pacific
is expected to showcase lucrative growth over the forecast period due to
rising per capita healthcare expenditure, improving healthcare facilities,
and demand for IVD testing for disease detection
- Increasing
R&D activities pertaining to cancer diagnostics and investment by
private and government sector into biotech industry in Asia Pacific are
the factors responsible for the growth
- Key players
operating in the Fluorescent In Situ Hybridization (FISH) probe market
include Oxford Gene Technology;
Mirus Bio LLC; Agilent Technologies; Perkin Elmer Inc.; Genemed
Biotechnologies Inc.; Horizon Diagnostics; BioDot Inc.; Sigma Aldrich;
Life Science Technologies; GSP Research Institute Co., Ltd; Abnova
Corporation; Biosearch Technologies; F Hoffman La Roche AG; Bio Care
Medical LLC; EXIQON; and Affymetrix Panomics
About Us:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment